Update date
26 Feb 2026
- Info
- Insider Trading
- Financials
- Holders
Wave Life Sciences Ltd. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- WVE on Nasdaq
- Location
- Singapore, Singapore
- Fiscal year end
- 31 December
- Latest financial report
- 26 Feb 2026
Shareable Research Card
WVE - Wave Life Sciences Ltd. Financial Facts
WVE - Wave Life Sciences Ltd. has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.
Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.
- Context
- Latest metrics period: Q1 2026
- Latest reported value
- Return On Equity -55%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Return Loop
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2026.
- Most recent SEC facts end date on this page: 19 Feb 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for WVE - Wave Life Sciences Ltd.
Latest financial period: Q4 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Page type
Company facts
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 26 Feb 2026.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 28% versus the comparable prior period. It sits inside the middle range of the current industry benchmark sample.
Compared with
Compared with Wave Life Sciences Ltd.'s recent history and the latest same-industry benchmark sample for the same metric.
Why this is notable
Use the history link to verify the prior-period change, then compare that metric with the current industry middle range if you want broader context.
- Latest comparable period on this page: Q1 2026.
- Current industry benchmark sample: 675 companies.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Save this filer page
Create a free account to keep this page in your watchlists and return after a new SEC filing changes the record here.
Quick Takeaways
- WVE - Wave Life Sciences Ltd. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q1 2026.
- Headline metric: Return On Equity -55%.
What Changed
- Return On Equity YoY change: -28%.
- Most recent SEC facts end date: 19 Feb 2026.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Source Evidence
Based on latest 10-Q/10-K
See Original Filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest SEC snapshot (2026-02-19) highlights Return On Equity -55.0%, Return On Assets -27.2%, and Operating Margin -327.4%.
Compare This Company Through SEC-backed Metrics
Use these links to compare WVE - Wave Life Sciences Ltd. against other SEC filers on the same metric, then verify the company history from the paired facts page.
NetIncomeLoss YoY
Latest value: -111%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
22.3/100
Weak Confidence medium
Return On Equity
-55%
Metric score 0.0/100
Return On Assets
-27%
Metric score 0.0/100
Financial Health
- Current Ratio
- 6.47x
- Quick Ratio
- 6.35x
- Debt to Equity
- 0.03x
Strengths
Debt-to-equity
Watchpoints
Return On Equity, Return On Assets, and Operating Margin
Key metrics snapshot
Return On Equity
-55%
YoY: -28%
Industry median: -43% (n=675)
Return On Assets
-27%
YoY: +33%
Industry median: -47% (n=673)
Operating Margin
-327%
YoY:
Industry median: -121% (n=298)
Current Ratio
6.47x
YoY: +124%
Industry median: 3.39x (n=667)
Quick Ratio
6.35x
YoY: +132%
Industry median: 1.51x (n=289)
Debt-to-equity
0.03x
YoY: -77%
Industry median: 0.26x (n=530)
NetIncomeLoss YoY
-111%
YoY:
Industry median: -0.93% (n=641)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -55% | -28% |
| Return On Assets | -27% | +33% |
| Operating Margin | -327% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 6.47x | +124% |
| Quick Ratio | 6.35x | +132% |
| Debt-to-equity | 0.03x | -77% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| NetIncomeLoss YoY | -111% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 188,254,954 | +22% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY